Immunohistochemical analysis of prostate-specific antigen in female breast cancer

Journal of B.U.ON.

Volumn 9, Issue 2, 2004, Pages 183-186

  Ilvan, Sennur ^a   Celik, V ^a   Cetinaslan, I ^a   Calay, Z ^a   Ferahman, M ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Immunohistochemistry; Prognostic factors; Prospate specific antigen

Indexed keywords

ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; STEROID RECEPTOR; TUMOR MARKER;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; ONCOLOGICAL PARAMETERS; PAGET NIPPLE DISEASE; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; SAMPLING; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TUMOR VOLUME;

EID: 4344677230     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-1368.
2. Tell DT, Khoury JM, Taylor HG, Veasey SP. A typical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen. JAMA 1985; 253: 3574-3575.
3. Nowels K, Kent E, Rinsho K, Oyasu R. Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis. Arch Pathol Lab Med 1988; 112: 734-737.
4. Papotti M, Paties C, Peveri V, Moscuzza L, Bussolati G. Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors. Basic Appl Histochem 1989; 33: 25-29.
5. van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol 1993; 17: 410-414.
6. Yu H, Diamandis EP, Levesque M et a]. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40: 171-178.
7. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ. Immunohistochemical labelling for prostate specific antigen in nonprostatic tissues. Path Res Pract 1996; 192: 233-237.
8. Levesque M, Yu H, D'Costa M, Tadross L, Diamandis EP. Immunoreactive prostate specific-antigen in lung tumors. J Clin Lab Anal 1995; 9: 375-379.
9. Henttu P, Vihko P. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Ann Med 1994; 26: 157-164.
10. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166-3170.
11. McDonald RJ, Margolius HS, Erdos EG. Molecular biology of tissue kallikrein. Biochem J 1988; 253: 313-321.
12. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli EE. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 1987; 170: 111-120.
13. Yu H, Giai M, Diamandis EP et al. Prostate- specific antigen is a new favorable prognostic indicator for women with breast eancer. Cancer Res 1995; 55: 2104-2110.
14. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. Clin Cancer Res 1998; 4: 1489-1497.
15. Diamandis EP, Yu H, Sutherland DJ. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994; 32: 301-310.
16. Yu H, Diamandis EP, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994; 32: 291-300.
17. Romppanen J, Keskikuru R, Kataja V et al. Measurement of prostate-specific antigen in the detection of benign or malignant breast disease in women. Br J Cancer 1999; 79: 1583-1587.
18. Foekens JA, Diamandis EP, Yu H et al. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 1999; 79: 888-894.
19. Heyl W, Wolff JM, Biesterfeld S et al. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer. Anticancer Res 1999; 19: 2563-2566.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 1991; 19: 403-410.
21. Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 2000; 59: 1-14.
22. Kogan I, Ballinger JR, Redshaw R et al. Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. Breast Cancer Res Treat 1998; 48: 73-80.
23. Yu H, Diamandis EP, Monne M, Croce CM. Oral contraceptive-induced expression of pro state-specific antigen in the female breast. J Biol Chem 1995; 270: 6615-6618.
24. Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient agc. Clin Biochem 1994; 27: 75-79.
25. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate- specific antigen. J Natl Cancer Inst 1999; 91: 1635-1640.
26. Miller MK, Unger PD, Bleiweiss IJ. Immunohistochemical analysis of prostate specific. antigen in breast cancer. Breast Cancer Res Treat 2001; 68: 111-116.
27. Howarth DJ, Aronson IB, Diamandis,EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer 1997; 75: 1646-1651.
28. Alanen KA, Kuopio T, Collan YU, Kronqvist P, Juntti L, Nevalainen TJ. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas Breast Cancer Res Treat 1999; 56: 169-176.
29. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are coexpressed in androgen receptor-positive breast tumours. Br J Cancer 1998; 78: 360-365.
30. Griniatsos J, Diamantis E, Gioti J, Karyda I, Vassilopoulos PP, Agnanti N. Correlation of prostate specific antigen immunoreactivity (IR-PSA) to other prognostic factors in female breast cancer. Anticancer Res 1998; 18: 683-688.